BBG Advanced Therapies, part of nonprofit BioBridge Global, has partnered with Kite, a Gilead company, to deploy a Mobile Leukapheresis Center across Texas. This mobile unit collects T-cells from patients locally, reducing travel and logistical challenges for accessing Kite's CAR T-cell therapies, which are personalized cancer treatments. The initiative aims to increase treatment access for eligible patients by bringing the initial cell collection closer to home, serving as a model for expanding advanced therapy infrastructure. This collaboration supports broader adoption of cell therapies by improving convenience and maintaining high-quality standards throughout the treatment process.
Gilead Sciences reported a negative trailing twelve-month EPS of -$3.13 due to a large one-time charge in Q2 2026, but its quarterly dividend was raised to $0.82. The company’s free cash flow covers the dividend about 4.6 times, indicating strong cas...
Sanofi has decided to discontinue the Phase 1 clinical trial and development of SAR448272, an oral STAT6 degrader developed in collaboration with Nurix Therapeutics. As a result, Nurix will no longer receive milestone payments or royalties related to...
